{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:52:22Z","timestamp":1776937942893,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,23]]},"DOI":"10.7759\/cureus.107564","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:11:48Z","timestamp":1776935508000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and Tolerability of Vildagliptin 100 mg Sustained-Release Formulation in Type 2 Diabetes Mellitus: Results From a Prospective, Multicenter, Single-Arm, Post-marketing Surveillance Study"],"prefix":"10.7759","author":[{"given":"Pravin","family":"Soni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Sonawane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Gaidhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niddhi","family":"Baxi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deeksha","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shivani","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116464","article-title":"Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM)","volume":"272","author":"Shao DW","year":"2024","unstructured":"Shao DW, Zhao LJ, Sun JF. Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM). Eur J Med Chem. 2024, 272:116464. 10.1016\/j.ejmech.2024.116464","journal-title":"Eur J Med Chem"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v13i9.6222","article-title":"Pharmacokinetic and pharmacodynamics study of multiple oral doses of vildagliptin sustained release 100 mg tablets under the fed state in healthy volunteers","volume":"13","author":"Doshi C","year":"2023","unstructured":"Doshi C, Sridhar SB, Birla A, Prasad A, Kadam P, Warrier S. Pharmacokinetic and pharmacodynamics study of multiple oral doses of vildagliptin sustained release 100 mg tablets under the fed state in healthy volunteers. J Drug Deliv Ther. 2023, 13:107-13. 10.22270\/jddt.v13i9.6222","journal-title":"J Drug Deliv Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.47191\/ijcsrr\/V4-i5-19","article-title":"Comparative clinical pharmacokinetics and pharmacodynamics of investigational once-daily sustained-release (SR) vildagliptin 100 mg tablet formulation with conventional 50 mg twice-daily regimen in healthy Indian males","volume":"4","author":"Pote A","year":"2021","unstructured":"Pote A, Ravisankar S, Sangle G, et al.. Comparative clinical pharmacokinetics and pharmacodynamics of investigational once-daily sustained-release (SR) vildagliptin 100 mg tablet formulation with conventional 50 mg twice-daily regimen in healthy Indian males. Int J Curr Sci Res Rev. 2021, 4:445-56. 10.47191\/ijcsrr\/V4-i5-19","journal-title":"Int J Curr Sci Res Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39204","article-title":"Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review","volume":"15","author":"Sridhar GR","year":"2023","unstructured":"Sridhar GR, Pandit K, Warrier S, Birla A. Sustained-release vildagliptin 100 mg in type 2 diabetes mellitus: a review. Cureus. 2023, 15:e39204. 10.7759\/cureus.39204","journal-title":"Cureus"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1313","article-title":"Pharmacokinetics and food effect between a 100-mg sustained-release tablet and a 50-mg immediate-release tablet of vildagliptin in healthy subjects","volume":"13","author":"Yoo H","year":"2024","unstructured":"Yoo H, Shin W, Lee B, Park J, Lee Y, Kim A. Pharmacokinetics and food effect between a 100-mg sustained-release tablet and a 50-mg immediate-release tablet of vildagliptin in healthy subjects. Clin Pharmacol Drug Dev. 2024, 13:122-7. 10.1002\/cpdd.1313","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2008.10.009","article-title":"Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea","volume":"83","author":"Mohan V","year":"2009","unstructured":"Mohan V, Yang W, Son HY, et al.. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract. 2009, 83:106-16. 10.1016\/j.diabres.2008.10.009","journal-title":"Diabetes Res Clin Pract"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2015.39.4.304","article-title":"Effects of sitagliptin on insulin and glucagon levels in type 2 diabetes mellitus","volume":"39","author":"Kim JH","year":"2015","unstructured":"Kim JH. Effects of sitagliptin on insulin and glucagon levels in type 2 diabetes mellitus. Diabetes Metab J. 2015, 39:304-6. 10.4093\/dmj.2015.39.4.304","journal-title":"Diabetes Metab J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.146861","article-title":"Incretin response in Asian type 2 diabetes: are Indians different?","volume":"19","author":"Singh AK","year":"2015","unstructured":"Singh AK. Incretin response in Asian type 2 diabetes: are Indians different?. Indian J Endocrinol Metab. 2015, 19:30-8. 10.4103\/2230-8210.146861","journal-title":"Indian J Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v12i6.5760","article-title":"A comparative pharmacodynamic and pharmacokinetic study of Vildagliptin SR 100 mg tablet in normal healthy adult male subjects","volume":"12","author":"Warrier S","year":"2022","unstructured":"Warrier S, Joshi HR, Joshi N. A comparative pharmacodynamic and pharmacokinetic study of Vildagliptin SR 100 mg tablet in normal healthy adult male subjects. J Drug Deliv Ther. 2022, 12:22-6. 10.22270\/jddt.v12i6.5760","journal-title":"J Drug Deliv Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-SINT","article-title":"Introduction and methodology: standards of care in diabetes-2025","volume":"48","year":"2025","unstructured":"Introduction and methodology. standards of care in diabetes-2025. Diabetes Care. 2025, 48:S1-5. 10.2337\/dc25-SINT","journal-title":"Diabetes Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-022-01129-5","article-title":"RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022","volume":"42","year":"2022","unstructured":"RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int J Diabetes Dev Ctries. 2022, 42.1-143. 10.1007\/s13410-022-01129-5","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006299137","article-title":"Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT","volume":"47","author":"He YL","year":"2007","unstructured":"He YL, Wang Y, Bullock JM, et al.. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007, 47:633-41. 10.1177\/0091270006299137","journal-title":"J Clin Pharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008325152","article-title":"Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers","volume":"49","author":"Hu P","year":"2009","unstructured":"Hu P, Yin Q, Deckert F, et al.. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009, 49:39-49. 10.1177\/0091270008325152","journal-title":"J Clin Pharmacol"},{"key":"ref14","unstructured":"Galvus - Summary of product characteristics (EMA Annex I) (2013). 2013. https.\/\/www.ema.europa.eu\/en\/documents\/product-information\/galvus-epar-product-information_en.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S44646","article-title":"Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis","volume":"7","author":"Srivastava K","year":"2013","unstructured":"Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and meta-analysis. Patient Prefer Adherence. 2013, 7:419-34. 10.2147\/PPA.S44646","journal-title":"Patient Prefer Adherence"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231170034","article-title":"Prescription trends for preservative free glaucoma medication in a public health system","volume":"34","author":"P\u00e9rez-Garc\u00eda P","year":"2024","unstructured":"P\u00e9rez-Garc\u00eda P, Burgos-Blasco B, Morales-Fern\u00e1ndez L, et al.. Prescription trends for preservative free glaucoma medication in a public health system. Eur J Ophthalmol. 2024, 34:193-203. 10.1177\/11206721231170034","journal-title":"Eur J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82549","article-title":"Efficacy and safety of vildagliptin sustained-release and metformin sustained-release fixed-dose combination in Indian patients with type 2 diabetes mellitus: a real-world perspective","volume":"17","author":"Sarda A","year":"2025","unstructured":"Sarda A, Sosale B, Jagan Mohan B, et al.. Efficacy and safety of vildagliptin sustained-release and metformin sustained-release fixed-dose combination in Indian patients with type 2 diabetes mellitus: a real-world perspective. Cureus. 2025, 17:e82549. 10.7759\/cureus.82549","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00473-8","article-title":"Effectiveness and safety of vildagliptin sustained release in the management of type 2 diabetes mellitus: real-world evidence in Indian patients [Novelty study]","volume":"12","author":"Sahay R","year":"2025","unstructured":"Sahay R, Bhansali A, Sharma SK, Iyer R, Sugumaran A, Mohanasundaram S, Gogtay J. Effectiveness and safety of vildagliptin sustained release in the management of type 2 diabetes mellitus: real-world evidence in Indian patients [Novelty study]. Drugs Real World Outcomes. 2025, 12:83-91. 10.1007\/s40801-024-00473-8","journal-title":"Drugs Real World Outcomes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2022.12.062851202217862022","article-title":"Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: a randomized, open label, Phase IV parallel group, and clinical trial","volume":"12","author":"Paul R","year":"2022","unstructured":"Paul R, Ghosh A, Sengupta N, Sahana P. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: a randomized, open label, Phase IV parallel group, and clinical trial. Natl J Physiol Pharm Pharmacol. 2022, 12:1229-32. 10.5455\/njppp.2022.12.062851202217862022","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.47363\/JPRSR\/2024(5)163","article-title":"Assessing patient profiles and outcomes with vildagliptin 100 mg sustained release (SR) in individuals diagnosed with type 2 diabetes mellitus","author":"Chawla R","year":"2024","unstructured":"Chawla R, Bantwal G, George J, Warrier S, Gupta A. Assessing patient profiles and outcomes with vildagliptin 100 mg sustained release (SR) in individuals diagnosed with type 2 diabetes mellitus. J Pharm Res Rep. 2024, 1-5. 10.47363\/JPRSR\/2024(5)163","journal-title":"J Pharm Res Rep"},{"key":"ref21","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH E6(r3). guideline for good clinical practice. (2025). Accessed: March 12, 2026: https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf."},{"key":"ref22","unstructured":"Ministry of Health and Family Welfare, Government of India. New Drugs and Clinical Trials Rules, 2019. (2019). Accessed. March 12, 2026: https:\/\/cdsco.mohfw.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=OTg4OA==."},{"key":"ref23","article-title":"The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994","unstructured":"The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Little, Brown & Co, Boston, MA; 1994. https:\/\/books.google.co.in\/books\/about\/Nomenclature_and_Criteria_for_Diagnosis.html?id=Vs5qQgAACAAJ&redir_esc=y."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1104604","article-title":"Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy","volume":"41","author":"Goodman M","year":"2009","unstructured":"Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009, 41:368-73. 10.1055\/s-0028-1104604","journal-title":"Horm Metab Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9396-8","article-title":"Metrics for the evaluation of bioequivalence of modified-release formulations","volume":"14","author":"Endrenyi L","year":"2012","unstructured":"Endrenyi L, Tothfalusi L. Metrics for the evaluation of bioequivalence of modified-release formulations. AAPS J. 2012, 14:813-9. 10.1208\/s12248-012-9396-8","journal-title":"AAPS J"},{"key":"ref26","article-title":"Patient-centered assessment of the efficacy and safety of vildagliptin sustained-release tablet (100 mg) relative to sitagliptin (100 mg) in patients with type 2 diabetes mellitus inadequately controlled on metformin (Prime-Vilda trial)","volume":"13","author":"Zargar AH","year":"2025","unstructured":"Zargar AH, Gupta S, Jaganmohan B, Warrier S, Farista F, Patil C. Patient-centered assessment of the efficacy and safety of vildagliptin sustained-release tablet (100 mg) relative to sitagliptin (100 mg) in patients with type 2 diabetes mellitus inadequately controlled on metformin (Prime-Vilda trial). Med Res Arch. [online] . 2025, 13:","journal-title":"Med Res Arch. [online]"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/470165-safety-and-tolerability-of-vildagliptin-100-mg-sustained-release-formulation-in-type-2-diabetes-mellitus-results-from-a-prospective-multicenter-single-arm-post-marketing-surveillance-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T09:11:54Z","timestamp":1776935514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/470165-safety-and-tolerability-of-vildagliptin-100-mg-sustained-release-formulation-in-type-2-diabetes-mellitus-results-from-a-prospective-multicenter-single-arm-post-marketing-surveillance-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.107564","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,23]]}}}